The discovery of targeted bacteria capable of rescuing antibiotic-associated dysbiosis made it feasible to promote anti-tumor efficacy by modulating microbiome diversity, especially for HER2-positive BC patients. This evidence concerns the gene ERBB2 and breast cancer.